Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASCO 2019 /
BYLieve study results: Alpelisib and endocrine therapy in patients with PIK3CA-mutated/HR /HER2- advanced breast cancer

31st May - 4th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 12.06.19
Views: 1085

Prof Hope Rugo - University of California, San Francisco, USA

Prof Hope Rugo speaks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about the results from the BYLieve study.

She describes the aim and methodology of the study, which was to assess the efficacy and toxicity of alpelisib in combination with endocrine therapy in patients who have received prior CDK4/6 inhibitors.

Prof Rugo also discusses the results from this interim analysis, which includes reasonable response rates which was in accordance with the data achieved in the SOLAR-1 study. A much lower discontinuation rate was also achieved in this study.

She believes the use of PI3-kinase inhibitors, such as alpelisib is an exciting advancement in personalising treatments for breast cancer.


Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation